AstraZeneca starts global recall of its controversial Covid 19 vaccine

AstraZeneca starts global recall of its controversial Covid 19 vaccine

08 May 2024

Days after admitting that its Covid 19 vaccine could cause blood clot in some people, British-Swedish pharmaceutical company AstraZeneca

AstraZeneca to buy China's Gracell Biotechnologies for $1.2 bn

AstraZeneca to buy China's Gracell Biotechnologies for $1.2 bn

27 Dec 2023

Anglo-Swedish multinational pharmaceutical and biotechnology company AstraZeneca has agreed to acquire China-based Gracell Biotechnologies Inc, for about $1.2 billion.

AstraZeneca to acquire CinCor Pharma in a deal worth $1,8 bn

11 Jan 2023

AstraZeneca to acquire biotech firm TeneoTwo in a deal worth more than $1.27 billion

08 Jul 2022

AstraZeneca to acquire Alexion in a $39 bn cash-and-stock deal

23 Dec 2020

India may grant emergency use authorisation for Oxford-AstraZeneca Covid-19 vaccine: report

24 Nov 2020

AstraZeneca Covid-19 vaccine trial volunteer in Brazil dies; testing to continue

26 Oct 2020

Sun Pharma licenses AstraZeneca to sell its oncology drugs in China

06 Nov 2019

AstraZeneca and Merck claim Japanese approval for anti-cancer drug Lynparza

20 Jun 2019

AstraZeneca in $6.9 bn deal with Daiichi Sankyo for cancer drug development

29 Mar 2019

Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.

Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!

Start your free subscription today!

Latest articles on AstraZeneca from Informachine

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

25 Nov 2024

Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

18 Nov 2024

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

12 Nov 2024

Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial

12 Nov 2024

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

12 Nov 2024

9M and Q3 2024 results

12 Nov 2024

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

08 Nov 2024

AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024

07 Nov 2024

AZN share price movement

06 Nov 2024

AstraZeneca China President currently under investigation

30 Oct 2024

View details about the software product Informachine News Trackers